Media headlines about Alliqua BioMedical (NASDAQ:ALQA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alliqua BioMedical earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.825212860974 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
Shares of NASDAQ:ALQA traded up $0.02 during midday trading on Friday, reaching $2.21. The company’s stock had a trading volume of 10,207 shares, compared to its average volume of 18,377. The company has a market cap of $11.06 million, a P/E ratio of -0.34 and a beta of 0.94. Alliqua BioMedical has a 1 year low of $1.58 and a 1 year high of $4.60.
Separately, ValuEngine raised Alliqua BioMedical from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Receive News & Ratings for Alliqua BioMedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical and related companies with MarketBeat.com's FREE daily email newsletter.